Xenetic Biosciences, Inc. (NASDAQ: XBIO) is headquartered in Lexington, Massachusetts, USA and has 5 full-time employees. It is a clinical-stage biopharmaceutical company focusing on the discovery, research and development of next-generation biologic drugs and new orphan tumor drugs.
Xenetic Biosciences (XBIO):
Xenetic Biosciences’ main research product candidate is the tumor treatment XBIO-101 (Cridamod sodium), which is used to treat progesterone-resistant endometrial cancer.
In addition, PolyXen, Xenetic’s patented drug development platform, enables the next generation of biopharmaceuticals by improving its half-life and other pharmacological properties.
Xenetic Biosciences is conducting business development activities to explore partnerships using its PolyXen delivery platform. The company has signed R&D, licensing and supply agreements with Shire plc , Serum Institute of India, PJSC Pharmsynthez and SynBio LLC.
